Broncho-Munal P caps. 3,5mg # 10

Release form

Hard gelatin capsules, size No. 3, opaque, with a white body and a blue lid

the contents of the capsules are light beige powder.

Packaging

10 pieces.

- blisters (1) - cardboard packs.

pharmachologic effect

An immunomodulatory drug of bacterial origin.

Modulates the body's immune response, stimulates cellular and humoral immunity.

Reduces the frequency and severity of infections, thereby reducing the need for antibiotics.

Pharmacokinetics.

Data on the pharmacokinetics of Broncho-Munal are not provided.

Indications

infectious diseases of the respiratory tract (as part of complex therapy as an immunomodulatory agent) in children aged 6 months to 12 years (for capsules 3.5 mg)

infectious diseases of the respiratory tract (as part of complex therapy as an immunomodulatory agent) in adults and children over the age of 12 years (for 7 mg capsules)

for the prevention of recurrent infections of the upper and lower respiratory tract (chronic bronchitis, tonsillitis, pharyngitis, laryngitis, rhinitis, sinusitis, otitis media).

Contraindications

Increased individual sensitivity to drug components.

Application during pregnancy and lactation

The use of the drug Broncho-munal during pregnancy and lactation is possible only if the intended benefit to the mother outweighs the potential risk to the fetus or infant.

special instructions

A 4-week interval should be observed between the use of oral vaccines and the intake of Broncho-munal.

It is not recommended to use the drug for acute intestinal diseases due to a possible decrease in the effectiveness of the drug.

Use in pediatrics

The drug is not prescribed for children under 6 months of age.

To avoid overdose, children from 6 months to 12 years old are prescribed only Broncho-munal P (capsules containing 3.5 mg of lyophilisate).

Influence on the ability to drive vehicles and use mechanisms

No special precautions required.

Structure

1 caps .: lyophilized bacterial lysate: Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Streptococcus viridans, Streptococcus pyogenes, Moraxella catarrhalis 3.5 mg

Excipients: propyl gallate (anhydrous), sodium glutamate (anhydrous), mannitol, magnesium stearate, pregelatinized starch, indigotin, titanium dioxide, gelatin.

Method of administration and dosage

Adults and children over 12 years of age are prescribed Broncho-munal at a dose of 7 mg

children aged 6 months to 12 years are prescribed Broncho-munal P at a dose of 3.5 mg.

The drug is taken in the morning on an empty stomach, 1 caps / day.

If the patient / child cannot swallow the capsule, it is recommended to open it and dissolve the contents of the capsule in a small amount of liquid (tea, milk or juice).

For the prevention of infectious diseases of the respiratory tract, the drug is used in three 10-day courses with 20-day intervals between them.

In the acute period of the disease, 1 capsule / day is prescribed until the symptoms of the disease disappear, but not less than 10 days.

In the next 2 months, prophylactic use of the drug in 1 caps is possible

within 10 days with a 20-day interval between courses.

Side effects

During the entire period of clinical use of the drug, undesirable effects were recorded extremely rarely.

In some cases: disorders of the digestive system (epigastric pain, nausea, vomiting, diarrhea), increased body temperature.

If the side effects are mild, drug withdrawal is not required.

If a hypersensitivity reaction occurs, it is recommended to cancel the drug.

Drug interactions

The drug can be used concurrently with other medicines, including antibiotics.

Overdose

There were no clinical symptoms of overdose.

There are no reports of intoxication due to

Name ENG

BRONCHO-MUNAL P

Clinical and pharmacological group

Immunostimulating drug of bacterial origin

ATX code

Other immunostimulants

Dosage

3.5mg

Structure

1 caps .: lyophilized bacterial lysate: Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Streptococcus viridans, Streptococcus pyogenes, Moraxella catarrhalis 3.5 mg.

Excipients: propyl gallate (anhydrous), sodium glutamate (anhydrous), mannitol, magnesium stearate, pregelatinized starch, indigotin, titanium dioxide, gelatin.

Indications

Respiratory tract infections (as part of complex therapy as an immunomodulatory agent) in children aged 6 months to 12 years (for 3.5 mg capsules)

infectious diseases of the respiratory tract (as part of complex therapy as an immunomodulatory agent) in adults and children over the age of 12 (for 7 mg capsules)

for the prevention of recurrent infections of the upper and lower respiratory tract (chronic bronchitis, tonsillitis, pharyngitis, laryngitis, rhinitis, sinusitis, otitis media).

Storage conditions and periods

At a temperature of 15-25 degrees.

Expiration date: 5 years

Contraindications

Increased individual sensitivity to drug components.

Application during pregnancy and lactation

The use of the drug Broncho-munal during pregnancy and lactation is possible only if the intended benefit to the mother outweighs the potential risk to the fetus or infant.

INN / Active ingredient

lyophilized bacterial lysates: Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus viridans, Streptococcus pyogenes, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis

Specifications

Category

Cough

Scope of the drug

Respiratory system

Release form

Capsules

Manufacturer country

Slovenia

Package quantity, pcs

ten

Minimum age from

6 months

Vacation conditions

Without recipe

Brand name

Sandoz

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Immunostimulating agent

Anatomical and therapeutic characteristics

L03AX Other immunostimulants

Dosage form

Capsules

Expiration date in days

1825

The target audience

Children

Package weight, g

15

Mode of application

:

Adults and children over 12 years of age are prescribed Broncho-munal at a dose of 7 mg

children aged 6 months to 12 years are prescribed Broncho-munal P at a dose of 3.5 mg.

< br> The drug is taken in the morning on an empty stomach, 1 capsule / day.

If the patient / child cannot swallow the capsule, it is recommended to open it and dissolve the contents of the capsule in a small amount of liquid (tea, milk or juice).

< br> For the prevention of infectious diseases of the respiratory tract, the drug is used in three 10-day courses with 20-day intervals between them.

< br> In the acute period of the disease, 1 capsule / day is prescribed until the symptoms of the disease disappear, but not less than 10 days.

In the next 2 months, prophylactic use of the drug in 1 caps is possible

within 10 days with a 20-day interval between courses.

Dosage (volume) of the substance in the preparation

:

lyophilized bacterial lysate: Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Streptococcus viridans, Streptococcus pyogenes, Moraxella catarrhalis 3.5 mg

Information on technical characteristics, delivery set, country of manufacture